BDTX Stock Summary and Trading Ideas (Black Diamond Therapeutics | NASDAQ:BDTX)

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.

As of January 23, 2026, BDTX stock price declined to $2.61 with 760,483 million shares trading.

BDTX has a beta of 1.93, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.22 to the broad based SPY ETF.

BDTX has a market cap of $148.60 million. This is considered a Micro Cap stock.

In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.

The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, VXF, FESM, IBB, DFAS.

BDTX has underperformed the market in the last year with a price return of +4.4% while the SPY ETF gained +14.2%. BDTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.7% and -7.1%, respectively, while the SPY returned +2.9% and -0.7%, respectively.

BDTX support price is $2.56 and resistance is $2.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.